(Q43039768)

12 November 2017

title

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients (English)

1 reference

12 November 2017

1 reference

1 reference

8

Stefan Zeuzem

1 reference

12 November 2017

Tara L Kieffer

1

1 reference

12 November 2017

Christoph Sarrazin

2

1 reference

12 November 2017

Janice S Miller

3

1 reference

12 November 2017

Martin W Welker

4

1 reference

12 November 2017

Nicole Forestier

5

1 reference

12 November 2017

Hendrik W Reesink

6

1 reference

12 November 2017

Ann D Kwong

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

12 November 2017

1 reference

12 November 2017

volume

46

1 reference

12 November 2017

issue

3

1 reference

12 November 2017

page(s)

631-639

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

12 November 2017

cites work

1 reference

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

7 January 2021

Past, present, and future hepatitis C treatments

1 reference

7 January 2021

Treating HCV with ribavirin analogues and ribavirin-like molecules

1 reference

7 January 2021

Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.

1 reference

7 January 2021

The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice

1 reference

7 January 2021

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

7 January 2021

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

1 reference

7 January 2021

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay

1 reference

7 January 2021

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

1 reference

7 January 2021

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

1 reference

7 January 2021

In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance

1 reference

7 January 2021

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

1 reference

7 January 2021

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

1 reference

7 January 2021

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

1 reference

7 January 2021

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

1 reference

7 January 2021

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

1 reference

7 January 2021

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

7 January 2021

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

7 January 2021

Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21781

1 reference

12 November 2017

1 reference